M2 Pharma - Therapy Areas - Inflammatory Disease

AcuCort granted US trademark protection for ISICORT

3 March 2021 - Swedish pharmaceutical company AcuCort AB (Spotlight:ACUC) said on Wednesday that the US Patent and Trademark Office (USPTO) has granted trademark protection to the company's drug ...

UK study by Oxford University to test gout drug as potential COVID-19 treatment

3 March 2021 - Researchers at University of Oxford said on 3 March 2021 that a large UK study looking into potential early-stage COVID-19 treatments will begin testing gout medication colchicine and h...

WHO's expert panel issues strong advice against hydroxychloroquine for COVID-19

2 March 2021 - An expert panel of the World Health Organisation (WHO) said on 2 March 2021 that the drug hydroxychloroquine should not be used to prevent COVID-19 and has no meaningful effect on patie...

US FDA Accepts US Merck's Gefapixant New Drug Application for Review

2 March 2021 - - The US Food and Drug Administration has accepted for review US-based pharmaceutical company Merck's (NYSE: MRK) New Drug Application for gefapixant, an investigational, orally ad...

First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

2 March 2021 - - US-based biopharmaceutical company Ocular Therapeutix, Inc. (NASDAQ: OCUL) has dosed the first patient in its Phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthal...

SARPAC Clinical Trial of Leukine in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function

1 March 2021 - - US-based biotechnology company Partner Therapeutics, Inc. has released top-line results of the investigator-led SARPAC (Sargramostim in Patients with Acute Hypoxic Respirato...